Thrombotic outcomes and mortality with roxadustat for anemia in chronic kidney disease: a systematic review and meta-analysis of randomized trials.

Regarding VAT, roxadustat was associated with a borderline significant increase in odds in the ESA-controlled stratum (OR: 1.40; 95% CI: 1.00–1.96; I 2 = 0.0%); in contrast, the placebo-controlled estimate was statistically unstable owing to zero-event arms (OR: 3.52; 95% CI: 0.00–401,207.67), which rendered the CI uninformative.

also in 11,409 other papers